{
    "nct_id": "NCT03742986",
    "official_title": "Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)",
    "inclusion_criteria": "* Newly diagnosed inflammatory breast cancer without distant metastases and have not received prior chemotherapy or immunotherapy. All breast cancer subtypes are allowed: Triple negative breast cancer (TNBC); Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; HR-positive or HR-negative and HER2-positive\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinical or radiologic evidence of distant metastases\n* Malignancy that progressed within the last five years.\n* Cardiac disease (history of and/or active disease)\n* HIV positive\n* Neuropathy â‰¥ Grade 2, per the NCI CTCAE v5.0\n* Allogeneic stem cell or solid organ transplantation\n* Autoimmune disease where in the opinion of the Investigator would preclude the use of immunotherapy\n* Idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), or evidence of active pneumonitis\n* Tuberculosis\n* Pregnancy or lactation\n* Treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunosuppressive medications\n* Cardiopulmonary dysfunction\n* Clinically significant history of liver disease, including cirrhosis, autoimmune hepatic disorders, HIV infection, or active Hepatitis B or Hepatitis C\n* Subject is pregnant or nursing\n* Known hypersensitivity to the components of the study drugs(s)",
    "miscellaneous_criteria": ""
}